Last reviewed · How we verify
NCT06698484: CAR-T for NHL
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
Phase 2 trial testing CAR-T cells in Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma in 20 participants. Currently enrolling.
2 June 2025
Quick facts
| Lead sponsor | National University of Malaysia |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 3 June 2021 |
| Primary completion | 2 June 2025 |
| Estimated completion | 2 June 2026 |
| Sites | 1 location across Malaysia |
Drugs / interventions tested
- CAR-T cells
Conditions studied
- Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma — all drugs for Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma →
Sponsor
National University of Malaysia
Who can join
Adults 13 to 75, any sex, with Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
Abdul Wahid SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al · · 2025 · cited 1× · PMID 40425809 · DOI 10.1038/s41409-025-02629-8
Verify or expand the search:
- PubMed search for NCT06698484
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T cells
Trials testing the same drug.
- NCT06481228 — Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL · NA · recruiting
- NCT06429150 — Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma · Phase 1, PHASE2 · recruiting
- NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
- NCT05779917 — Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers · Phase 1 · recruiting
- NCT05420493 — Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Ly · Phase 1 · unknown
Other National University of Malaysia trials
Trials by the same sponsor.
- NCT07251842 — Metabolic Availability of Methionine in Tempeh Chips Among Reproductive-age Women Using Indicator Amino Acid Oxidation ( · NA · not yet recruiting
- NCT07362394 — Autologous Dentine Graft Compared to Xenograft in Managing Periodontally Compromised Second Molar After Third Molar Remo · NA · not yet recruiting
- NCT07503223 — Sleep Optimization With Acoustic Therapy · NA · recruiting
- NCT07432373 — Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection · not yet recruiting
- NCT07157397 — Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06698484 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University of Malaysia
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06698484.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing